Mechanisms of action of liver contrast agents: Impact for clinical use

Journal of Computer Assisted Tomography

Volumn 23, Issue SUPPL., 1999, Pages

  Clément, Olivier ^a   Siauve, Nathalie ^a   Cuénod, Charles André ^a   Vuillemin Bodaghi, Valérie ^a   Leconte, Isabelle ^a   Frija, Guy ^a  

^a Hopital Boucicaut   (France)

Author keywords

Contrast agents; Gadolinium; Iron; Liver; Manganese; MRI

Indexed keywords

GADOLINIUM; IRON; MANGANESE;

CLINICAL USE; CONTRAST AGENT; ENDOTHELIAL SYSTEMS; GADOLINIA; HEPATOBILIARY; HEPATOCYTES; INTRAVENOUS INJECTIONS; MECHANISM OF ACTION; NANO PARTICULATES; PHARMACEUTICAL COMPANY;

MAGNETIC RESONANCE IMAGING;

CHELATING AGENT; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERIC ACID; GADOTERIDOL; MANGAFODIPIR; MANGANESE; SUPERPARAMAGNETIC IRON OXIDE;

CONFERENCE PAPER; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CANCER; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; SIGNAL PROCESSING;

EID: 0343114281     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004728-199911001-00007     Document Type: Conference Paper

References (49)

1. Peterson MS, Baron RL, Murakami T. Hepatic malignancies: usefulness of acquisition of multiple arterial and portal venous phase images at dynamic gadolinium-enhanced MR imaging. Radiology 1996;201:337-45.
2. Soyer P. CT during arterial portography. Eur Radiol 1996;6:349-57.
3. Friedman BR, Jones JP, Chavez-Munoz G, Salmon AP, Merritt CR. Principles of MRI. New York: McGraw-Hill, 1989.
4. Jackals SC. Enhancement agents for magnetic resonance imaging. In: Pharmaceuticals in Medical Imaging. Swanson DP, Chilton HM, Thrall JH, eds. New York: Macmillan, 1990: Chapter 20.
5. Schuhmann-Giampieri G. Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging. Invest Radiol 1993;28:753-61.
6. Kirchin MA, Pirovano G, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 1998;33:798-809.
7. Weinmann HJ, Laniado M, Mützel W. Pharmacokinetics of Gd-DTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984;16:167-72.
8. McLachlan SJ, Eaton S, De Simone DN. Pharmacokinetic behavior of gadoteridol injection. Invest Radiol 1992;27:S12-5.
9. Le Mignon MM, Chambon C, Warrington S, Davies R, Bonnemain B. Gd-DOTA: pharmacokinetics and tolerability after intravenous injection into healthy volunteers. Invest Radiol 1990;25:933-7.
10. Van Wagoner M, O'Toole M, Worah D, Leese PT, Quay SC. A phase I clinical trial with gadodiamide injection, a non-ionic magnetic resonance imaging enhancement agent. Invest Radiol 1991;26: 980-6.
11. Hamm B, Thoeni RF, Gould RG, et al. Focal liver lesions: characterization with nonenhanced and dynamic contrast-material-enhanced MR imaging. Radiology 1994;190:417-23.
12. Ohtomo K, Itai Y, Yoshikawa K, et al. Hepatic tumors: dynamic MR imaging. Radiology 1987;163:27-31.
13. Hamm B, Mahfouz AE, Taupitz M, et al. Liver metastases: improved detection with dynamic gadolinium-enhanced MR imaging? Radiology 1997;202:677-82.
14. Baron RL. Detection of liver neoplasms: techniques and outcomes. Abdom Imaging 1994;19:320-4.
15. Ferrucci JT. Ferrite particles: rationale and clinical results (midfield). In: Liver imaging: current trends and new techniques. Ferrucci JT, Stark DD, eds. Boston: Andover Medical Publishers, 1990:403-14.
16. Seltzer SE. The role of liposomes in diagnostic imaging. Radiology 1989;171:19-21.
17. Unger EC. Liposomal Gd-DTPA: effect of encapsulation on enhancement of hepatoma model by MRI. Magn Res Imaging 1989;7:417-23.
18. Rozenman Y, Zou X, Kantor HL. Signal loss induced by superparamagnetic iron oxide particles in NMR spin-echo images: the role of diffusion. Magn Res Med 1990;14:31-9.
19. Majumdar S, Zoghbi SS, Gore JC. The influence of pulse sequence on the relaxation effects of superparamagnetic iron oxide contrast agent. Magn Res Med 1989;10:289-301.
20. Senéterre E, Taourel P, Bouvier Y, et al. Detection of hepatic metastases: ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography. Radiology 1996;200: 785-92.
21. Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR 1989;152:167-73.
22. Oswald PO, Clément O, Chambon C, Schouman-Claeys E, Frija G. Liver positive enhancement after injection of superparamagnetic nanoparticles: respective role of circulating and uptaken particles. Magn Reson Imaging 1997;15:1025-31.
23. Small WC, Nelson RC, Bernadino ME. Dual contrast enhancement of both T1-and T2-weighted sequences using ultrasmall superparamagnetic iron oxide. Magn Reson Imaging 1993;11:645-54.
24. Chambon C, Clément O, Le Blanche A, Schouman-Clayes E, Frija G. Superparamagnetic iron oxides as positive MR contrast agents: in vitro and in vivo evidence. Magn Reson Imaging 1993;11:509-19.
25. Grangier C, Tourniaire J, Mentha G, et al. Enhancement of liver hemangiomas on T1-weighted MR SE images by superparamagnetic iron oxide particles. J Comput Assist Tomogr 1994;18:888-96.
26. Ros PR, Freeny PC, Harms SE, et al. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 1995;196:481-8.
27. Denys A, Arrivé L, Servois V, et al. Hepatic tumors: detection and characterization at IT MR imaging enhanced with AMI-25. Radiology 1994;193:665-9.
28. Hagspiel KD, Neidl KFW, Eichenberger AC, Weder W, Marincek B. Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. Radiology 1995;196:471-78.
29. Grandin C, Van Beers B, Robert A, Gigot JF, Geubel A, Pringot J. Benign hepatocellular tumors: MRI after superparamagnetic iron oxide administration. J Comput Assist Tomogr 1995;19:412-8.
30. Torres CG, Lundby B, Tufte Sterud A, McGill S, Gordon PB, Strand Bjerknes H. MnDPDP for MR imaging of the liver. Results from the European phase III studies. Acta Radiol 1997;38:631-7.
31. Rummeny EJ, Torres CG, Kurdziel JC, Nilsen G, Op de Beeck B, Lundby B. MnDPDP for MR imaging of the liver. Results of an independent image evaluation of the European phase III studies. Acta Radiol 1997;38:638-42.
32. Wang C, Gordon PB, Hustvedt O, et al. MR imaging properties and pharmacokinetics of MnDPDP in healthy volunteers. Acta Radiol 1997;38:665-76.
33. Rummeny E, Ehrenheim C, Gehl HB, et al. Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of liver tumors. Invest Radiol 1991;26:S142-5.
34. Wang C, Ahlström H, Ekholm S, et al. Diagnostic efficacy of Mn-DPDP in MR imaging of the liver: a phase III multicentre study. Acta Radiol 1997;38:643-9.
35. Bernadino ME, Young SW, Lee JKT, Weinreb JC. Hepatic MR imaging with Mn-DPDP: safety, image quality and sensitivity. Radiology 1992;183:53-8.
36. Giovagnoni A, Paci E. Liver III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). MRI Clin North Am 1996;4:61-72.
37. Rosati G, Pirovano G, Spinazzi A. Interim results of phase II clinical testing of gadobenate dimeglumine. Invest Radiol 1994;29:S183-5.
38. Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimegumine: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 1999;6:282-91.
39. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects and pulse sequence. Radiology 1996;199:177-83.
40. Hamm B, Staks T, Mühler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics and MR imaging. Radiology 1995;195:785-92.
41. van Montfoort JE, Stieger B, Meijer DKF, Meier PJ, Fattinger KE. Transport of the liver specific MRI-contrast agent Gd-EOB-DTPA by the rat organic anion transporting polypeptide OATP1. Hepatology 1998;28:180A (Abstract).
42. de Haën C, La Ferla R, Maggioni F. Gadobenate dimeglumine 0.5 M solution for injection (MultiHance®) as contrast agent for magnetic resonance imaging of the liver: mechanistic studies in animals. J Comput Assist Tomogr 1999; 23(suppl 1):S169-79.
43. Clément O, Mühler A, Vexier V, Berthezène Y, Brasch RC. Gd-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats. Invest Radiol 1992;27:612-9.
44. de Haën C, Gozzini L. Soluble-type hepatobiliary contrast agents for MR imaging. JMRI 1993;3:179-86.
45. de Haën C, Lorusso V, Tirone P. Hepatic transport of gadobenate dimeglumine in TR-rats. Acad Radiol 1996,3:S452-4.
46. Cupelli F, Pascolo L, Anelli PL, et al. ATP-dependent transport of magnetic resonance imaging (MRI) contrast agents in rat liver canalicular vesicles and yeast. Abstract submitted to EASL, 1999.
47. Spinazzi A, Davies A, Villa A, Campani R, Meloni G, Cavagna F. Current and future perspectives of research for new MR contrast media. Radiol Med 1997;93:36-45.
48. Spinazzi A, Lorusso V, Pirovano GP, Taroni P, Kirchin M, Davies A. MultiHance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 1998;5:S86-9.
49. Hamm B, Kirchin M, Pirovano G, Spinazzi A. Clinical utility and safety of MultiHance® in magnetic resonance imaging of liver cancer: results of multicenter studies in Europe and the USA. J Comput Assist Tomogr 1999; 23(suppl 1):S53-60.